VEKIRAX + EXVIERA
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HCV Coinfection
Conditions
HCV Coinfection
Trial Timeline
Jun 22, 2017 → Nov 28, 2018
NCT ID
NCT03050905About VEKIRAX + EXVIERA
VEKIRAX + EXVIERA is a approved stage product being developed by AbbVie for HCV Coinfection. The current trial status is completed. This product is registered under clinical trial identifier NCT03050905. Target conditions include HCV Coinfection.
What happened to similar drugs?
1 of 2 similar drugs in HCV Coinfection were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03050905 | Approved | Completed |
Competing Products
3 competing products in HCV Coinfection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Boceprevir, Peg-interferon alfa 2b and Ribavirin | Merck | Phase 2 | 35 |
| Peginterferon Alfa-2 | Roche | Phase 3 | 32 |
| Maraviroc + Placebo | Pfizer | Approved | 43 |